Sexually transmitted diseases in Europe break record

In 2019, the number of reported cases of bacterial sexually transmitted diseases (STDs) in Europe reached a record high of 17 million, while the number of cases also increased 49% of new HIV diagnoses Between 2010 and 2019, a total of 1.5 million cases. This is the conclusion reached by researchers led by the Center for HIV/STI Research at Kamruti Campus, a pioneering research ‘centre’ in this field globally, and highlights the rise of these diseases in Europe over the past decade. Resurrection. , which is a worrying public health issue.

This research, made public through a series of four articles published in The Lancet Regional Health Europe, advances analysis and approaches to sexually transmitted diseases, reorienting prevention and control strategies. And, despite huge advances in diagnosis and treatment, data show significant declines in the transmission of these diseases, hampering the goal of eliminating the HIV, viral hepatitis and sexually transmitted disease epidemics.

Data were compiled for the study, which was coordinated by Dr. Oriol Mitjà of the Foundation to Fight Infection and the Trias i Pujol University Hospital in Germany Epidemiological data from 49 European countries.

Northern and western regions of Europe have higher incidence rates per 100,000 inhabitants, “This may be due to the presence of more stringent surveillance and case notification systems,” they said. The series also highlights new key populations such as immigrants, refugees, sex workers and men who have sex with men who have limited access to health services.

The researchers also pointed to healthcare disparities and resource shortages in some countries as major obstacles to European prevention and control strategies.

In addition to the discouraging data provided by the report, it also highlights the need for Maintain sex education and promote condom useor used in conjunction with other biomedical interventions. “There is a need to promote equity in HIV pre-exposure prophylaxis (PrEP), which has been introduced in 38 of the region’s 53 countries but remains underutilized, particularly in Central and Eastern European countries,” the authors insist It is believed that cabotegravir, the first long-acting antiretroviral drug, has the potential to revolutionize PrEP for HIV because it is given as an injection every two months rather than taking the drug every day.

Regarding vaccines, they pointed to progress in controlling infections. Viral hepatitis A and B, and HPV. “The future lies in the control of gonorrhea through cross-immunity generated by meningococcal type B vaccines, and in mRNA-based vaccines for HIV immunity,” they said.

For its part, treating bacterial sexually transmitted diseases, e.g. Gonorrhea, mycoplasma and syphilis, They present significant challenges due to increasing antimicrobial resistance and, in some cases, a lack of solutions due to a lack of scientific research in this area. Current strategies have fallen behind, so new approaches, such as rapid diagnostic tests, are needed to reduce the overuse of antibiotics when infections go undiagnosed.